Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex.

NPJ Vaccines · 2022 · PMC9610341 · PMID 36302778

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

RhAd52.CoV.Consv (Group 5) led to a nonsignificant trend of a 0.5 log reduction of virus in the lungs (median: 7E3 PFU/lobe) and a significant 1.5 log reduction of virus in nasal turbinates (median: 5500 PFU/nasal turbinate) compared to sham controls ( P = 0.0079).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.